Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study

Table 3 Univariate analyses comparing factors associated with continuation or withdrawal of treatment with mirogabalin

Variables	Continued treatment (n= 163)	Withdrew from treatment (n= 24)	pvalue
Age (years)	71.8 ± 12.7 (30–94)	75.0 ± 9.9 (49–91)	0.23^a
Sex, female/male	110/53	19/5	0.25^b
Diagnosis			0.98^b
LCS	118	17
CSM	28	5
LDH	9	1
CTS	8	1
Others	1	0
BMI (kg/m²)	22.9 ± 4.1 (18–33)	23.2 ± 3.9 (19–31)	0.78^a
DM	15	2	0.89^b
Adverse events with pregabalin
Somnolence	92 (56.4%)	5 (20.8%)	0.0017^b
Dizziness	39 (23.9%)	11 (45.8%)	0.015^b
Edema	4 (2.5%)	3 (12.5%)	0.012^b
Weight gain	3 (1.8%)	0 (0%)	0.51^b
Others	2 (1.2%)	2 (8.3%)
Lack of efficacy with pregabalin	27 (16.6%)	5 (20.8%)	0.61^b
NeP score (points)	7.0 ± 1.7 (6–12)	6.9 ± 1.7 (6–12)	0.80^b
Primary dose of mirogabalin (mg)	3.1 ± 1.2 (5–10)	3.3 ± 1.8 (5–10)	0.52^b
Adverse events with mirogabalin
Somnolence	44 (27%)	6 (25%)	0.84^b
Dizziness	16 (9.8%)	7 (29.2%)	0.0069^b
Edema	7 (4.3%)	4 (16.7%)	0.016^b
Epigastric pain	0 (0%)	2 (8.3%)	< 0.0001^b
Weight gain	1 (0.6%)	0 (0%)	0.70^b
Fatigue	1 (0.6%)	0 (0%)	0.70^b

Data are expressed as the mean ± standard deviation (range) or n (%).
LCS lumbar canal stenosis, CSM cervical spondylotic myelopathy, LDH lumbar disc herniation, CTS carpal tunnel syndrome, BMI body mass index, DM diabetes mellitus, NeP neuropathic pain
^a Student’s t-test
^b Chi-squared test

ISSN: 1749-799X